Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.63 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etilamfetamine SCHEMBL27754453 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| Etilamfetamine SCHEMBL162316 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| Etilamfetamine SCHEMBL16866783 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| Etilamfetamine SCHEMBL727383 | 0.98 | SIGMAR1 (0.96) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| Etilamfetamine SCHEMBL1650086 | 0.96 | SIGMAR1 (0.92) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL29059547 | 0.84 | SIGMAR1 (0.81) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL9134313 | 0.83 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL711506 | 0.83 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| N-Benzylamphetamine SCHEMBL2798189 | 0.83 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| N-Benzylamphetamine SCHEMBL2795222 | 0.83 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1558 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | claimed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | claimed |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | NORTHEASTERN UNIVERSITY | 2016-03-10 | — | — | US | claimed |
| US-20150272920-A1 | METHOD FOR TREATING OBESITY WITH ANTI-OBESITY FORMULATIONS AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS | PIVOTAL THERAPEUTICS INC. (CA) | 2015-10-01 | — | — | US | claimed |
| EP-2814478-A1 | A METHOD FOR TREATING OBESITY WITH ANTI-OBESITY FORMULATIONS AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS | Pivotal Therapeutics, Inc. (CA) | 2014-12-24 | — | — | EP | claimed |
| US-20140288454-A1 | Method For Using Exhaled Breath to Determine the Presence of Drug | Pulmonary Analytics (US) | 2014-09-25 | — | — | US | claimed |
| US-8715648-B2 | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics | PIVOTAL THERAPEUTICS INC. (CA) | 2014-05-06 | — | — | US | claimed |
| EP-2675444-A1 | A FORMULATIONS COMPRISING OMEGA 3 FATTY ACIDS AND AN ANTI OBESITY AGENT FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS | Pivotal Therapeutics, Inc. (CA) | 2013-12-25 | — | — | EP | claimed |
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | SITKOVSKY MICHAIL V (US) | 2013-12-05 | — | — | US | claimed |
| WO-2013122622-A1 | A METHOD FOR TREATING OBESITY WITH ANTI-OBESITY FORMULATIONS AND OMEGA 3 FATTY ACIDS FOR THE REDUCTION OF BODY WEIGHT IN CARDIOVASCULAR DISEASE PATIENTS (CVD) AND DIABETICS | PIVOTAL THERAPEUTICS, INC. (CA) | 2013-08-22 | — | — | WO | claimed |
| WO-2002000221-A1 | ENHANCED BRAIN FUNCTION BY GABA-ERGIC STIMULATION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2002-01-03 | — | — | WO | claimed |
| EP-1165054-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | Pharmaquest Limited (BM) | 2002-01-02 | — | — | EP | claimed |
| JP-2001524960-A | — | — | 2001-12-04 | — | — | JP | claimed |
| US-6217904-B1 | MIXTURES; ADMINISTERING IN CYCLES | PHARMAQUEST LTD. (BM) | 2001-04-17 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000059481-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000059479-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0977572-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047513-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | SLC6A3, SLC6A2, CES2 | SIGMAR1 78/4885CYP1A2 70/4885CYP3A4 30/4885 |
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | ADORA2A, ADORA3, ADORA1 | SIGMAR1 261/4885CYP1A2 788/4885CYP3A4 1769/4885 |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | SIGMAR1 67/4885CYP1A2 56/4885CYP3A4 25/4885 |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | ADORA2A, ADORA3, ADORA1 | SIGMAR1 261/4885CYP1A2 788/4885CYP3A4 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.